Table 3. Positive PET–SUV uptake and subsequent local recurrence (n=24).

Maximum FDG-SUV	Site of FDG-SUV uptake	Local recurrence	Site of local recurrence	Time to LR from completion of RT (months)
33	Primary	Yes	Nodes (and lung)	17
30	Other (nasopharynx—original primary oropharynx)	No	–	–
21.9	Primary	Yes	Primary	8
19.5	Primary	Yes	Primary	6
14.6	Primary	Yes	Primary (and lung)	10
13.3	Primary	Yes	Primary and nodes	4
12.1	Primary	Yes	Primary	4
11.1	Other (larynx—original primary oropharynx)	Yes	Primary and nodes	19
11.0	Nodes	Yes	Nodes	7
10.2	Primary	Yes	Primary and nodes	3
7.3	Primary	No	–	–
6.7	Primary	No	–	–
6.6	Other (nasopharynx—original primary oropharynx)	No	–	–
5.5	Primary	Yes	Primary	12
5.3	Primary	Yes	Primary	30
5	Primary	No	–	–
4.9	Primary	No	–	–
4.7	Nodes	No	–	–
4.7	Nodes	Yes	Nodes	4
4.6	Nodes	No	–	–
4.6	Other (supraglottis—original primary oropharynx)	No	–	–
4.4	Primary	Yes	Primary and nodes	9
4.3	Primary	No	–	–
3.9	Nodes	Yes	Nodes	8
3.9	Primary	No	–	–
3.8	Nodes	Yes	Nodes	3
3.5	Nodes	No	–	–
3.2	Nodes	Yes	Nodes	5
3.1	Nodes	Yes	Nodes	6
3.1	Nodes	No	–	–
3.1	Nodes	No	–	–

FGD, 2-[¹⁸F]-fluoro-2-deoxy-d-glucose; LR, local recurrence; RT, radiotherapy; SUV, standardised uptake value.